Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”

messenger RNA (mRNA)-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccines such as BNT162b2 became available in late 2020, but hematological malignancy patients (HM pts) were not evaluated in initial registration trials. We hereby report the results of a prospective, unicentric, obser...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Sara, Lucchini, Elisa, Sirianni, Francesca, Porrazzo, Marika, Ballotta, Laura, Ballerini, Mario, De Sabbata, Giovanni Maria, De Bellis, Eleonora, Cappuccio, Ilaria, Granzotto, Marilena, Toffoletto, Barbara, Fortunati, Ilaria, Russignan, Anna, Florea, Emilia Elzbieta, Torelli, Lucio, Zaja, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008958/
https://www.ncbi.nlm.nih.gov/pubmed/36923438
http://dx.doi.org/10.3389/fonc.2023.1133348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008958/
https://www.ncbi.nlm.nih.gov/pubmed/36923438
http://dx.doi.org/10.3389/fonc.2023.1133348

Ejemplares similares